Neuronetics IncNASDAQ:STIM
- LAST PRICE3.4900
- TODAY'S CHANGE (%)-0.0300 (-0.8523%)
- Bid / Lots2.7000/ 4
- Ask / Lots4.6500/ 1
- Open / Previous Close3.5200 / 3.5200
- Day Range
- 52 Week Range
- Volume44,573
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | STIM |
|---|---|---|
| 09:32 ET | 1093 | 3.52 |
| 10:32 ET | 100 | 3.345 |
| 10:33 ET | 2580 | 3.4365 |
| 10:35 ET | 200 | 3.44 |
| 10:39 ET | 200 | 3.4508 |
| 10:46 ET | 427 | 3.37 |
| 10:48 ET | 1400 | 3.415 |
| 10:50 ET | 200 | 3.46 |
| 10:55 ET | 892 | 3.43 |
| 11:00 ET | 249 | 3.43 |
| 11:04 ET | 999 | 3.5 |
| 11:06 ET | 1835 | 3.53 |
| 11:08 ET | 211 | 3.53 |
| 11:09 ET | 100 | 3.51 |
| 11:13 ET | 100 | 3.49 |
| 11:27 ET | 363 | 3.49 |
| 11:31 ET | 100 | 3.46 |
| 11:42 ET | 100 | 3.46 |
| 11:51 ET | 300 | 3.47 |
| 11:56 ET | 200 | 3.49 |
| 12:05 ET | 500 | 3.5 |
| 12:18 ET | 3370 | 3.5 |
| 12:20 ET | 3574 | 3.5 |
| 12:21 ET | 300 | 3.47 |
| 12:23 ET | 121 | 3.475 |
| 12:25 ET | 100 | 3.475 |
| 12:38 ET | 250 | 3.475 |
| 12:39 ET | 250 | 3.4869 |
| 12:41 ET | 1300 | 3.5 |
| 12:57 ET | 186 | 3.495 |
| 01:10 ET | 400 | 3.5 |
| 01:48 ET | 100 | 3.5241 |
| 01:53 ET | 100 | 3.5 |
| 02:09 ET | 200 | 3.5 |
| 02:18 ET | 100 | 3.51 |
| 02:24 ET | 300 | 3.51 |
| 02:31 ET | 100 | 3.51 |
| 02:44 ET | 100 | 3.51 |
| 02:47 ET | 100 | 3.51 |
| 03:00 ET | 200 | 3.52 |
| 03:03 ET | 201 | 3.52 |
| 03:07 ET | 100 | 3.52 |
| 03:09 ET | 200 | 3.53 |
| 03:32 ET | 100 | 3.525 |
| 03:36 ET | 100 | 3.51 |
| 03:41 ET | 100 | 3.5 |
| 03:43 ET | 4037 | 3.48 |
| 03:45 ET | 100 | 3.48 |
| 03:48 ET | 1000 | 3.46 |
| 03:50 ET | 400 | 3.47 |
| 03:54 ET | 400 | 3.47 |
| 03:56 ET | 1600 | 3.48 |
| 03:57 ET | 800 | 3.5 |
| 03:59 ET | 1577 | 3.49 |
Apr 23, 2024
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call, from 4:30PM ET on Tuesday Apr 23, 2024 by Dow Jones
4:30PM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 10, 2024
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital, from 8:31AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:31AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neuronetics Inc | 104.6M | -3.3x | --- |
Butterfly Network Inc | 162.1M | -1.2x | --- |
Vaso Corp | 49.8M | 9.5x | --- |
Vapotherm Inc | 7.7M | -0.1x | --- |
NantHealth Inc | 16.3M | -0.1x | --- |
Venus Concept Inc | 4.3M | -0.1x | --- |
Company Information
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Contact Information
- Headquarters
- 3222 Phoenixville PikeMALVERN, PA, United States 19355
- Phone
- 610-640-4202
- Fax
- 610-640-4206
Executives
- Independent Non-Executive Chairman of the Board
- Robert Cascella
- President, Chief Executive Officer, Director
- Keith Sullivan
- Chief Financial Officer, Executive Vice President, Treasurer
- Stephen Furlong
- Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
- W. Andrew Macan
- Senior Vice President - Research & Development and Clinical
- Cory Anderson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $104.6M |
|---|---|
Revenue (TTM) | $71.3M |
Shares Outstanding | 30.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.49 |
EPS | $-1.06 |
Book Value | $1.18 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -42.82% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
